TPN-101

Transposon Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	TPN-101
Also known as	censavudine
Sponsor	Transposon Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TPN-101 in Aicardi-Goutières Syndrome (AGS) (PHASE2)
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (PHASE2)
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TPN-101 CI brief — competitive landscape report
TPN-101 updates RSS · CI watch RSS
Transposon Therapeutics, Inc. portfolio CI